PRESS RELEASE published on 08/15/2025 at 15:21, 7 months 25 days ago enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech enVVeno Medical Corporation to present at Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 21, 2025, with CEO Robert Berman discussing innovative treatment solutions for deep venous disease Webinar EnVVeno Medical Corporation Bioprosthetic Solutions Deep Venous Disease Webull Financial
BRIEF published on 08/06/2025 at 14:35, 8 months 3 days ago VenoValve d'enVVeno Medical : une solution rentable pour les IVC sévères EnVVeno Medical Insuffisance Veineuse Chronique Approbation De La FDA Économies Sur Les Coûts Des Soins De Santé Valve VenoValve
BRIEF published on 08/06/2025 at 14:35, 8 months 3 days ago EnVVeno Medical's VenoValve: A Cost-Effective Solution for Severe CVI FDA Approval EnVVeno Medical VenoValve Chronic Venous Insufficiency Healthcare Cost Savings
PRESS RELEASE published on 08/06/2025 at 14:30, 8 months 3 days ago Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency Preliminary findings show VenoValve as cost-effective & clinically beneficial for severe CVI. Webcast discussing results. Potential $5.9B annual healthcare savings. Study shows cost savings and clinical benefits Webcast VenoValve Healthcare Savings CVI Cost-Effectiveness
BRIEF published on 08/04/2025 at 15:10, 8 months 5 days ago EnVVeno Medical Explores Potential Impact of Trump's CVI Diagnosis on Treatment Options FDA Approval VenoValve CVI Diagnosis Trump Impact Healthcare Cost
BRIEF published on 08/04/2025 at 15:10, 8 months 5 days ago EnVVeno Medical étudie l'impact potentiel du diagnostic d'IVC de Trump sur les options de traitement. Approbation De La FDA Valve VenoValve Diagnostic De L'IVC L'impact De Trump Coût Des Soins De Santé
PRESS RELEASE published on 08/04/2025 at 15:05, 8 months 5 days ago enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company enVVeno Medical is developing the VenoValve as a potential treatment for Chronic Venous Insufficiency. FDA decision expected in 2H'2025 EnVVeno Medical VenoValve Chronic Venous Insufficiency FDA Decision Deep Venous Disease
BRIEF published on 08/01/2025 at 14:05, 8 months 8 days ago EnVVeno Medical Q2 2025 Financial Report and Corporate Update EnVVeno Medical VenoValve Q2 2025 Results EnVVe Progress FDA Decision
BRIEF published on 08/01/2025 at 14:05, 8 months 8 days ago Rapport financier et mise à jour de l'entreprise d'enVVeno Medical pour le deuxième trimestre 2025 EnVVeno Medical Valve VenoValve Résultats Du Deuxième Trimestre 2025 Progrès EnVVe Décision De La FDA
PRESS RELEASE published on 08/01/2025 at 14:00, 8 months 8 days ago enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update enVVeno Medical reports $3.8M cash burn & financial results for Q2 2025. Operations funded through Q3'2026 with sufficient cash. FDA decisions & clinical program progress on track Financial Results EnVVeno Medical Cash Burn FDA Decisions Clinical Program Progress
Published on 04/10/2026 at 02:15, 3 hours 34 minutes ago Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
Published on 04/10/2026 at 01:05, 4 hours 44 minutes ago Pathfinder Ventures Inc. Announces Tranche Closing of Financing and Extension of Private Placement
Published on 04/10/2026 at 00:00, 5 hours 49 minutes ago Redwood AI Announces Upgraded Cloud-Based Reactosphere Platform with Enhanced Security and Expanded Core Capabilities
Published on 04/09/2026 at 23:15, 6 hours 34 minutes ago Digi Power X Enters into Amended and Restated Sales Agreement
Published on 04/09/2026 at 22:00, 7 hours 49 minutes ago Invitation - First Quarter 2026 Trading Update Conference Call
Published on 04/09/2026 at 21:01, 8 hours 48 minutes ago GEVELOT S.A.: PRESS RELEASE CLOSING OF 2025 ACCOUNTS
Published on 04/09/2026 at 21:01, 8 hours 48 minutes ago GEVELOT S.A.: COMMUNIQUE ARRETE DES COMPTES 2025
Published on 04/09/2026 at 20:03, 9 hours 46 minutes ago Annual General Meeting approves all proposals
Published on 04/09/2026 at 18:45, 11 hours 4 minutes ago EUROPLASMA: Tirage de 200 obligations convertibles en actions nouvelles pour un montant nominal de 1M€
Published on 04/09/2026 at 20:00, 9 hours 49 minutes ago SMTPC - Communiqué sur le Chiffre d'affaires du 1er trimestre 2026
Published on 04/09/2026 at 18:35, 11 hours 14 minutes ago Mise à disposition des documents préparatoires à l'Assemblée Générale Mixte du 30 avril 2026
Published on 04/09/2026 at 18:35, 11 hours 14 minutes ago Availability of proxy documents for the Combined General Meeting of April 30, 2026